10:24 AM EST - Knight Therapeutics Inc : Announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer which has continued to spread after at least two previous treatment for advanced cancer. Knight Therapeutics Inc
shares T.GUD are trading up $0.03 at $5.29.
